Skip to search formSkip to main contentSkip to account menu

itolizumab

A humanized IgG1 monoclonal antibody targeting the T-cell differentiation antigen CD6, with immunmodulating activity. Itolizumab binds to CD6… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Antibodies, Monoclonal, Humanized
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
CD6 is a co-stimulatory receptor expressed on T cells that binds activated leukocyte cell adhesion molecule (ALCAM), a ligand… 
2018
2018
Failure of a T cell regulator: CD6 contributes to the aggravation of autoimmune inflammation
2018
2018
CD6 monoclonal antibodies differ in epitope, kinetics and mechanism of action
CD6 is a type I T‐cell surface receptor that modulates antigen receptor signalling. Its activity is regulated by binding of its… 
2017
2017
Itolizumab – A New Biologic for Management of Psoriasis and Psoriatic Arthritis
Psoriasis is a chronic, relapsing, inflammatory, immune-mediated systemic disease with mainly skin and joint manifestations. The… 
2017
2017
Itolizumab in the Management of Psoriasis with Metabolic Syndrome.
  • S. Parasramani
  • Journal of clinical and diagnostic research…
  • 2017
  • Corpus ID: 11093803
Psoriasis is a chronic, relapsing, inflammatory disease that has been associated with Metabolic Syndrome (MS), a cluster of… 
2016
2016
Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions
Psoriasis is a common, chronic, immune mediated, inflammatory disease of skin characterized by red patches enclosed with white… 
2016
2016
USE OF ITOLIZUMAB IN CHRONIC PLAQUE PSORIASIS PATIENTS: CLINICAL EXPERIENCE
Psoriasis is a common skin disease which carries a significant physical and psychological burden. The impact of the disease is… 
2014
2014
Anticuerpo monoclonal humanizado itolizumab (anti-cd6) en síndromes linfoproliferativos cd 6+. Experiencia preliminar
Introduccion: la molecula CD6 es una glicoproteina de membrana considerada un antigeno de diferenciacion leucocitario. El… 
2014
2014
Drugs in Clinical Development for Rheumatoid Arthritis Summary and Table
2011
2011
Artritis Reumatoide: beneficios clínicos observados en pacientes tratados con anticuerpo monoclonal Itolizumab. (T1h mAB), 2 años después de recibir tratamiento
La perdida de  la capacidad  funcional es  junto con  el  dolor la  consecuencia  mas temida de los pacientes  con  artritis… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)